ZOE Science & Nutrition

Should you take Ozempic? The 5 things you need to know before starting GLP-1 drugs | Dr Ania Jastreboff

94 snips
Apr 30, 2026
Guest
Dr. Ania Jastreboff
Dr Ania Jastreboff, physician-scientist and director of Yale Obesity Research Center, led major GLP-1 trials and co-wrote Enough. She explains how GLP-1 drugs recalibrate appetite and why weight often returns after stopping. She outlines health benefits beyond weight, differences between drugs like Ozempic and tirzepatide, key side effects to expect, and practical dosing and lifestyle tips to use them safely.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
ANECDOTE

Patients Discovered Food Noise By Losing It

  • Patients describe 'food noise' as intrusive thoughts about eating that vanishes on GLP-1 therapy.
  • Dr. Ania Jastreboff notes clinicians only recognised food noise after patients reported its disappearance on the drugs.
INSIGHT

How Pharma Trials Stay Scientifically Rigorous

  • Industry-funded trials are standard and undergo FDA oversight, academic authorship and independent peer review.
  • Investigators write drafts, integrate feedback, and journals use external peer reviewers to ensure rigor and transparency.
ADVICE

Don't Microdose Outside Trial Populations

  • Avoid microdosing or using GLP-1s outside studied populations until risk–benefit data exist.
  • The drugs haven't been studied for people without overweight or obesity, so safety and benefit are unknown.
Get the Snipd Podcast app to discover more snips from this episode
Get the app